TABLE 1.
Baseline characteristics of TB patients receiving SXT (n = 12)
| Parameter | Value [median (IQR)] |
|---|---|
| Age (yr) | 30 (25–50) |
| Gender (male/female) | 10/2 |
| Body mass index (kg/m2) | 20.2 (18.7–22) |
| Ethnicity | |
| Europe | 6 |
| Africa | 3 |
| America | 1 |
| Middle East | 1 |
| Western Pacific region | 1 |
| Co morbidity | |
| Smoking | 6 |
| Alcohol abuse | 4 |
| Illicit drug | 1 |
| Diabetes mellitus | 1 |
| Anemia | 1 |
| Anorexia | 1 |
| Localization of TB | |
| Pulmonary | 11a |
| Extrapulmonary (pleural and spinal) | 1 |
| Other anti-TB drugs | Isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin |
| Sodium level (mmol/liter) | 140 (139–141.2) |
| Potassium level (mmol/liter) | 4 (3.7–4.2) |
| Creatinine clearance (ml/min/1.73 m2) | 103.2 (106.0–112.0) |
| Platelet count (× 109/liter) | 292 (235.5–394.7) |
a
One of the 12 patients was diagnosed with both pulmonary and extrapulmonary TB.